Voyager Therapeutics’ (VYGR) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a report issued on Tuesday morning,Benzinga reports. They currently have a $25.00 price objective on the stock. HC Wainwright also issued estimates for Voyager Therapeutics’ Q1 2026 earnings at ($0.28) EPS, Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.28) EPS, Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.09) EPS, Q1 2027 earnings at ($0.28) EPS, Q2 2027 earnings at ($0.28) EPS, Q3 2027 earnings at ($0.24) EPS, Q4 2027 earnings at ($0.22) EPS, FY2027 earnings at ($1.34) EPS, FY2028 earnings at ($1.60) EPS, FY2029 earnings at ($1.35) EPS and FY2030 earnings at ($0.91) EPS.

Separately, Wall Street Zen upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Voyager Therapeutics currently has an average rating of “Hold” and an average target price of $16.50.

Voyager Therapeutics Trading Down 0.5%

Shares of NASDAQ VYGR opened at $3.74 on Tuesday. The stock has a market cap of $222.90 million, a P/E ratio of -1.84 and a beta of 1.32. The business’s fifty day simple moving average is $3.91 and its 200-day simple moving average is $4.19. Voyager Therapeutics has a 12-month low of $2.64 and a 12-month high of $5.55.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Monday, March 9th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.08. Voyager Therapeutics had a negative return on equity of 51.35% and a negative net margin of 296.53%.The firm had revenue of $13.46 million during the quarter, compared to analysts’ expectations of $10.49 million. On average, equities analysts forecast that Voyager Therapeutics will post -0.91 EPS for the current fiscal year.

Insider Activity

In other news, CEO Alfred Sandrock sold 14,197 shares of Voyager Therapeutics stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $3.79, for a total transaction of $53,806.63. Following the completion of the sale, the chief executive officer directly owned 484,060 shares of the company’s stock, valued at approximately $1,834,587.40. The trade was a 2.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders have sold 49,783 shares of company stock worth $188,694. 6.39% of the stock is currently owned by insiders.

Institutional Trading of Voyager Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of VYGR. Bank of Montreal Can purchased a new stake in Voyager Therapeutics during the 2nd quarter worth about $36,000. Wexford Capital LP purchased a new position in shares of Voyager Therapeutics in the 3rd quarter valued at about $42,000. ProShare Advisors LLC acquired a new stake in shares of Voyager Therapeutics during the 4th quarter worth about $44,000. CIBC Asset Management Inc purchased a new stake in Voyager Therapeutics during the fourth quarter worth approximately $45,000. Finally, Los Angeles Capital Management LLC purchased a new stake in Voyager Therapeutics during the second quarter worth approximately $50,000. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Key Voyager Therapeutics News

Here are the key news stories impacting Voyager Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and raised several near‑term 2026 quarterly and full‑year EPS forecasts (Q1–Q4 2026 and FY2026 showed modest improvements), signaling improved near‑term expectations and keeping a $25 price target well above the current share price. Article Title
• Neutral Sentiment: Media coverage summarized analyst commentary on healthcare names including Voyager; these pieces provide background and analyst viewpoints but contain no new company‑specific data beyond the HC Wainwright notes. Article Title
• Negative Sentiment: Alongside the near‑term bumps, HC Wainwright trimmed several longer‑term EPS projections for FY2027–FY2030 (notably FY2027–FY2029 and FY2030 adjustments), lowering the multi‑year profitability outlook — a bearish factor for valuation given Voyager’s loss profile and need for clinical/operational execution to realize upside. Article Title

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.